Abstract
Thrombotic microangiopathies (also referred to as microangiopathic hemolytic anemias) are a heterogeneous group of disorders which include thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, among others. Although therapeutic plasma exchange is often requested for the treatment of these disorders, not all are responsive. Solve it!
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:323–4.
Wynick C, Britto J, Sawler D, Parker A, Karkhaneh M, Goodyear D, Sun HL. Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients admitted to hospitals in Alberta with suspected thrombotic thrombocytopenic purpura. Blood. 2019;134(Suppl 1):2379.
Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost. 2015;113(4):708–18.
Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, Novembrino C, Boscolo Anzoletti M, De Zan V, Pagliari MT, Gualtierotti R, Aliberti S, Panigada M, Grasselli G, Blasi F, Peyvandi F. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19(2):513–21.
Feng S, Eyler SJ, Zhang Y, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013;122(8):1487–93.
Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017;189(4):E153–9.
Grall M, Daviet F, Chiche NJ, Provot F, Presne C, Coindre J-P, et al. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrol. 2021;22:267. https://doi.org/10.1186/s12882-021-02470-3.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:319.
Alexion Pharmaceuticals, Inc. SOLIRIS® prescribing information. Boston: Alexion Pharmaceuticals, Inc.; 2020.
Stefanello B, De Paula EV, Andrade Orsi F, Comenalli Marques JF Jr, Gasparotto Roveri E, Pereira Colella M, et al. Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation. J Clin Apher. 2014;29(6):311–5.
Further Reading
Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017;189(4):E153–9.
Grall M, Daviet F, Chiche NJ, Provot F, Presne C, Coindre J-P, et al. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrol. 2021;22:267.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). Gem City Fallout. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_83
Download citation
DOI: https://doi.org/10.1007/978-3-031-14638-1_83
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14637-4
Online ISBN: 978-3-031-14638-1
eBook Packages: MedicineMedicine (R0)